Lantern Pharma
LTRN
35 hedge funds and large institutions have $7.11M invested in Lantern Pharma in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 5 closing their positions.
800% more call options, than puts
Call options by funds: $108K | Put options by funds: $12K
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
9% more funds holding
Funds holding: 32 → 35 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.68% less ownership
Funds ownership: 22.56% → 20.87% (-1.7%)
17% less capital invested
Capital invested by funds: $8.62M → $7.11M (-$1.51M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$42.6K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$18.4K |
| 3 |
WIM
Westside Investment Management
Santa Monica,
California
|
+$17.7K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$11.7K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$10K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BIOS Capital Management
Fort Worth,
Texas
|
-$445K |
| 2 |
PWM
Perigon Wealth Management
San Francisco,
California
|
-$139K |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$101K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$52.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$11.6K |
LTRN Hedge Fund Activity: Q2 2025 in Review
35 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q2 2025, worth a combined $7.11M — down 17% from $8.62M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LTRN positions and 5 closed out — a net gain of 3 holders — while 11 added to existing stakes and 5 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $42.6K. The largest seller was BIOS Capital Management, cutting an estimated $445K.
- 35 institutional investors held Lantern Pharma (LTRN) as of Q2 2025, up from 32 in Q1 2025.
- Funds reported $7.11M of Lantern Pharma stock for Q2 2025, down 17% quarter-over-quarter.
- 8 funds opened new Lantern Pharma positions in Q2 2025 and 5 closed out, a net change of +3 holders.
- The largest Lantern Pharma buyer in Q2 2025 was XTX Topco, an estimated $42.6K added.
- The largest Lantern Pharma seller in Q2 2025 was BIOS Capital Management, an estimated $445K sold.
Based on aggregated 13F filings for Q2 2025.